Safety and Efficacy of the Therapy With BREINMAX® for the Treatment of Patients With Asthenia After COVID-19
Status:
Completed
Trial end date:
2022-11-10
Target enrollment:
Participant gender:
Summary
This is prospective multicentre comparative randomized double blind placebo controlled study
conducted in 6 medical facilities.The objective of the study is to assess the safety and
efficacy of the sequential therapy with BREINMAX®, solution for intravenous infusion and
intramuscular injection, and BREINMAX®, capsules for the treatment of patients with asthenia
after having the novel coronavirus infection (COVID-19)